Lauren Fairchild

Lauren Fairchild

Auto-generated profile, based on publicly available information

Lauren Fairchild

Novartis Pharmaceuticals Corporation, Cambridge, Massachusetts

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2023 in Science Translational Medicine
Verified
Journal Article
Closed access
LFLauren Fairchild
Lauren Fairchild
JWJeanne Whalen
Jeanne Whalen
KDKatie D’aCo
Katie D’aCo
JWJincheng Wu
Jincheng Wu
CGCarroll B. Gustafson
Carroll B. Gustafson
OBO. Alejandro Balbin
O. Alejandro Balbin
In the context of cancer, clonal hematopoiesis of indeterminate potential (CHIP) is associated with the development of therapy-related myeloid neoplasms and shorter overall survival. Cell-free DNA (cfDNA) sequencing is becoming widely adopted for genomic screening of patients with cancer but has not been used extensively to determine CHIP status because of a requirement for matched blood and tumor sequencing. We present an accurate classification approach to determine the CH status from cfDNA sequencing alone, applying our model to 4324 oncology clinical cfDNA samples. Using this method, we determined that 30.3% of patients in this cohort have evidence of CH, and the incidence of CH varies by tumor type. Matched RNA sequencing data show evidence of increased inflammation, especially neutrophil activation, within the tumors and tumor microenvironments of patients with CH. In addition, patients with CH had evidence of neutrophil activation systemically, pointing to a potential mechanism of action for the worse outcomes associated with CH status. Neutrophil activation may be one of many mechanisms, however, because patients with estrogen receptor–positive breast cancer harboring TET2 frameshift mutations had worse outcomes but similar neutrophil frequencies to patients without CH. Together, these data show the feasibility of detecting CH through cfDNA sequencing alone and an application of this method, demonstrating increased inflammation in patients with CH both systemically and in the tumor microenvironment.

1 June 2025 in Cancer Research Communications
Verified
Journal Article
Open access
LLLang Ho Lee
Lang Ho Lee
XXXin Xu
Xin Xu
TMThanos Mourikis
Thanos Mourikis
FTFanying Tang
Fanying Tang
LFLauren Fairchild
Lauren Fairchild
JWJincheng Wu
Jincheng Wu
Immune checkpoint inhibitors (ICI) have demonstrated clinical efficacy in non–small cell lung cancer (NSCLC), and extensive research has been conducted to explore biomarkers predictive of ICI response. However, the impact of ICI on the tumor and tumor microenvironment at primary and acquired resistance states is understudied due to the difficulty of collecting tissue biopsies at disease progression. In this study, we leveraged clinical and real-world data to study ICI resistance. Data used in this work consist of treatment outcome information and tissue RNA sequencing data from advanced-stage NSCLC cohorts from three sources: the Tempus real-world evidence database; CANOPY-1 (NCT03631199), a phase III clinical trial in first-line NSCLC; and Stand Up To Cancer (SU2C) publication. Our results indicate higher IFNγ and T-cell exhaustion in patients’ tumors at acquired resistance and low levels of B-cell and dendritic cell expression at primary resistance. The lower B-cell and dendritic cell levels may be primarily driven by prior treatment with a platinum-based chemotherapy regimen. Baseline transcriptomics data additionally suggest that innate immune cells may play an antitumor role in PD-L1<1% patients, whereas IFNγ and T-cell inflammation are more predictive of ICI treatment outcomes in PD-L1≥1% patients. Our study suggests a clear divergence of the tumor microenvironment in patients with primary versus acquired resistance and a potential role of myeloid cells in the PD-L1<1% population. These findings shed light on potential next-generation therapies to overcome ICI resistance. Significance: ICI benefits patients with NSCLC, but resistance remains common. Our research highlights differences in tumor environments between primary and acquired resistance after ICI treatment, emphasizing distinct post-therapy approaches. Findings also suggest myeloid cells as key players in PD-L1–negative cases, guiding future treatment strategies to overcome resistance and improve outcomes.

28 January 2024 in JHEP Reports
Verified
Journal Article
Open access
Armando SantoroArmando Santoro
Armando Santoro
EAEric Assenat
Eric Assenat
TYThomas Yau
Thomas Yau
JDJean-Pierre Delord
Jean-Pierre Delord
MMMichela Maur
Michela Maur
SCStephen L. Chan
Stephen L. Chan
This phase Ib/II trial evaluated the safety and efficacy of capmatinib in combination with spartalizumab or spartalizumab alone in patients with advanced hepatocellular carcinoma (HCC). Eligible patients who had progressed or were intolerant to sorafenib received escalating doses of capmatinib 200 mg, 300 mg, and 400 mg twice a day (bid) plus spartalizumab 300 mg every 3 weeks (q3w) in the phase Ib study. Once the recommended phase II dose (RP2D) was determined, the phase II study commenced with randomised 1:1 treatment with either capmatinib + spartalizumab (n = 32) or spartalizumab alone (n = 30). Primary endpoints were safety and tolerability (phase Ib) and investigator-assessed overall response rate per RECIST v1.1 for combination vs. single-agent arms using a Bayesian logistic regression model (phase II). In phase Ib, the RP2D for capmatinib in combination with spartalizumab was determined to be 400 mg bid. Dose-limiting toxicity consisting of grade 3 diarrhoea was reported in one patient at the capmatinib 400 mg bid + spartalizumab 300 mg q3w dose level. The primary endpoint in the phase II study was not met. The observed overall response rate in the capmatinib + spartalizumab arm was 9.4% vs. 10% in the spartalizumab arm. The most common any-grade treatment-related adverse events (TRAEs, ≥20%) were nausea (37.5%), asthenia and vomiting (28.1% each), diarrhoea, pyrexia, and decreased appetite (25.0% each) in the combination arm; TRAEs ≥10% were pruritus (23.3%), and rash (10.0%) in the spartalizumab-alone arm. Capmatinib at 400 mg bid plus spartalizumab 300 mg q3w was established as the RP2D, with manageable toxicities and no significant safety signals, but the combination did not show superior clinical activity compared with spartalizumab single-agent treatment in patients with advanced HCC who had previously been treated with sorafenib. Simultaneous targeting of MET and programmed cell death protein 1 may provide synergistic clinical benefit in patients with advanced HCC. This is the first trial to report a combination of capmatinib (MET inhibitor) and spartalizumab (programmed cell death protein 1 inhibitor) as second-line treatment after sorafenib for advanced HCC. The combination did not show superior clinical activity compared with spartalizumab single-agent treatment in patients with advanced HCC who had previously been treated with sorafenib. The results indicate that there is a clear need to identify a reliable predictive marker of response for HCC and to identify patients with HCC that would benefit from the combination of checkpoint inhibitor +/- targeted therapy. NCT02795429.

30 June 2025
Verified
Other
Open access
LLLang Ho Lee
Lang Ho Lee
XXXin Xu
Xin Xu
TMThanos Mourikis
Thanos Mourikis
FTFanying Tang
Fanying Tang
LFLauren Fairchild
Lauren Fairchild
JWJincheng Wu
Jincheng Wu
Table of differentially expressed gene table in primary resistance compared to treatment naïve cohort


30 June 2025
Verified
Other
Open access
PDF file
LLLang Ho Lee
Lang Ho Lee
XXXin Xu
Xin Xu
TMThanos Mourikis
Thanos Mourikis
FTFanying Tang
Fanying Tang
LFLauren Fairchild
Lauren Fairchild
JWJincheng Wu
Jincheng Wu
Distribution of biopsy tissue sites comparing the treatment-naïve group (cohort 1) with the post-ICI group (cohort 2) in the left two panels and contrasting primary resistance with acquired resistance within cohort 2 in the right two panels